u/Avish_Golakiya · 23h ago31 prior · 63% at 3mo
10 penny biotechs I'm watching and slowly adding for October/November 2026, and the one I got wrong in September.
RZLT has Phase 3 topline data expected mid-December for a rare disease program with a tiny trial and pre-BLA recommendation. The $352M cap and 24-month runway provide cushion, but Phase 3 readouts lack the predictable runup pattern of PDUFA catalysts.
At post $3.70Now $3.92+6.0% since postedas of Oct 22, 12:16 PM ET